2 January 2024FeaturesPharmaManita Rawat and Alexander Stein

2024 forecast: AI, patent eligibility and Fintiv

A few key items related to patents in the US are at the forefront of shaping our patent laws in 2024.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Atif Choudhury at achoudhury@lifesciencesipreview.com

More on this story

Pharma

Novartis pursues Apotex over copies of $2bn skin cancer drug franchise

8 October 2026 Following ANDA litigation over Tafinlar earlier this year, the Swiss multinational has sued the generics maker over its proposed version of Mekinist, asserting patents that cover both the composition and treatment regimen.

Pharma

MSD’s Keytruda hit by eight-country ban across Europe

8 October 2026 Rival Halozyme secures a major patent victory against the pharma giant, blocking the subcutaneous version of its blockbuster cancer drug Keytruda across eight countries as MSD faces mounting pressure ahead of key patent expirations.

Pharma

Dr Reddy’s v Boehringer: Data gaps take centre stage in courtroom

6 October 2026 Day one of the UK patent trial over blockbuster drug Jardiance put a lack of biological data, disputed evidence of testing and the limits of scientific prediction under the spotlight.

More features

Novartis pursues Apotex over copies of $2bn skin cancer drug franchise

MSD’s Keytruda hit by eight-country ban across Europe

Foley Hoag adds two partners in Denver expansion

WATCH: LEO Pharma head of IP rights on doing more with less

Dr Reddy’s v Boehringer: Data gaps take centre stage in courtroom

Latham adds ‘exceptional’ ITC expert and 5th trial lawyer in a year

Roche, Marques counsel: The fight against ‘deadly’ counterfeits is a race for the newest and best tech

Lilly loses Fed Circ rehearing bid, sparking enablement questions

2024 forecast: AI, patent eligibility and Fintiv

More on this story

Editor's picks

Editor's picks

More features